Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease

INTRODUCTION: Deep remission, defined as clinical remission with mucosal healing (MH), with anti-tumor necrosis factor (TNF)-α agents is a new target for therapy in Crohn’s disease (CD). Provided that the efficacy of infliximab (IFX) for induction of MH in CD has been demonstrated, there are much le...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Prz Gastroenterol
Egile Nagusiak: Szymanska, Edyta, Dadalski, Maciej, Grajkowska, Wieslawa, Szymanska, Sylwia, Pronicki, Maciej, Kierkus, Jaroslaw
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Termedia Publishing House 2016
Gaiak:
Original Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5360663/
https://ncbi.nlm.nih.gov/pubmed/28337236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/pg.2016.64746
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak